490 related articles for article (PubMed ID: 26403409)
1. IMP-3 EXPRESSION IN BENIGN MELANOCYTIC NEVI, DYSPLASTIC NEVI AND MALIGNANT MELANOMA: PRELIMINARY FINDINGS IN BULGARIAN PATIENTS.
Chokoeva AA; Ananiev J; Wollina U; Tana C; Lotti T; Cardoso JC; Tchernev G
J Biol Regul Homeost Agents; 2015; 29(3):695-9. PubMed ID: 26403409
[TBL] [Abstract][Full Text] [Related]
2. Beclin 1 and LC3 autophagic gene expression in cutaneous melanocytic lesions.
Miracco C; Cevenini G; Franchi A; Luzi P; Cosci E; Mourmouras V; Monciatti I; Mannucci S; Biagioli M; Toscano M; Moretti D; Lio R; Massi D
Hum Pathol; 2010 Apr; 41(4):503-12. PubMed ID: 20004946
[TBL] [Abstract][Full Text] [Related]
3. The significance of Ki-67 proliferative index and cyclin D1 expression of dysplastic nevi in the biologic spectrum of melanocytic lesions.
Lebe B; Pabuççuoğlu U; Ozer E
Appl Immunohistochem Mol Morphol; 2007 Jun; 15(2):160-4. PubMed ID: 17525627
[TBL] [Abstract][Full Text] [Related]
4. α-Methylacyl-coenzyme A racemase (AMACR, p504s) is a marker to distinguish malignant melanomas from dysplastic nevi and melanocytic nevi.
Abbas M; Ploch EM; Wehling J; Schipper E; Janciauskiene S; Kreipe HH; Jonigk D
Tumour Biol; 2014 Dec; 35(12):12015-20. PubMed ID: 25149154
[TBL] [Abstract][Full Text] [Related]
5. Atypical melanocytic nevi of the genital type with a discussion of reciprocal parenchymal-stromal interactions in the biology of neoplasia.
Clark WH; Hood AF; Tucker MA; Jampel RM
Hum Pathol; 1998 Jan; 29(1 Suppl 1):S1-24. PubMed ID: 9445124
[TBL] [Abstract][Full Text] [Related]
6. Alterations of mismatch repair protein expression in benign melanocytic nevi, melanocytic dysplastic nevi, and cutaneous malignant melanomas.
Hussein MR; Roggero E; Sudilovsky EC; Tuthill RJ; Wood GS; Sudilovsky O
Am J Dermatopathol; 2001 Aug; 23(4):308-14. PubMed ID: 11481522
[TBL] [Abstract][Full Text] [Related]
7. Benign melanocytic lesions: risk markers or precursors of cutaneous melanoma?
Skender-Kalnenas TM; English DR; Heenan PJ
J Am Acad Dermatol; 1995 Dec; 33(6):1000-7. PubMed ID: 7490345
[TBL] [Abstract][Full Text] [Related]
8. Expression of insulin-like growth factor-binding protein 2 in melanocytic lesions.
Wang H; Shen SS; Wang H; Diwan AH; Zhang W; Fuller GN; Prieto VG
J Cutan Pathol; 2003 Nov; 30(10):599-605. PubMed ID: 14744083
[TBL] [Abstract][Full Text] [Related]
9. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
Boyd AS; Shakhtour B; Shyr Y
J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
[TBL] [Abstract][Full Text] [Related]
10. Expression of the embryonic morphogen Nodal in cutaneous melanocytic lesions.
Yu L; Harms PW; Pouryazdanparast P; Kim DS; Ma L; Fullen DR
Mod Pathol; 2010 Sep; 23(9):1209-14. PubMed ID: 20495543
[TBL] [Abstract][Full Text] [Related]
11. A subgroup of melanocytic nevi on the distal lower extremity (ankle) shares features of acral nevi, dysplastic nevi, and melanoma in situ: a potential misdiagnosis of melanoma in situ.
Khalifeh I; Taraif S; Reed JA; Lazar AF; Diwan AH; Prieto VG
Am J Surg Pathol; 2007 Jul; 31(7):1130-6. PubMed ID: 17592281
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of cytoplasmic p27 expression in human melanoma.
Chen G; Cheng Y; Zhang Z; Martinka M; Li G
Cancer Epidemiol Biomarkers Prev; 2011 Oct; 20(10):2212-21. PubMed ID: 21828232
[TBL] [Abstract][Full Text] [Related]
13. WT1 and Bcl2 expression in melanocytic lesions of the conjunctiva: an immunohistochemical study of 123 cases.
Furusato E; Hidayat AA; Man YG; Auerbach A; Furusato B; Rushing EJ
Arch Ophthalmol; 2009 Aug; 127(8):964-9. PubMed ID: 19667332
[TBL] [Abstract][Full Text] [Related]
14. Cyclin D1 and D3 expression in melanocytic skin lesions.
Alekseenko A; Wojas-Pelc A; Lis GJ; Furgał-Borzych A; Surówka G; Litwin JA
Arch Dermatol Res; 2010 Sep; 302(7):545-50. PubMed ID: 20496072
[TBL] [Abstract][Full Text] [Related]
15. IMP-3 is a novel progression marker in malignant melanoma.
Pryor JG; Bourne PA; Yang Q; Spaulding BO; Scott GA; Xu H
Mod Pathol; 2008 Apr; 21(4):431-7. PubMed ID: 18204432
[TBL] [Abstract][Full Text] [Related]
16. The differential expression of micro-RNAs 21, 200c, 204, 205, and 211 in benign, dysplastic and malignant melanocytic lesions and critical evaluation of their role as diagnostic biomarkers.
Quiohilag K; Caie P; Oniscu A; Brenn T; Harrison D
Virchows Arch; 2020 Jul; 477(1):121-130. PubMed ID: 32388720
[TBL] [Abstract][Full Text] [Related]
17. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
18. The usefulness of c-Kit in the immunohistochemical assessment of melanocytic lesions.
Pilloni L; Bianco P; Difelice E; Cabras S; Castellanos ME; Atzori L; Ferreli C; Mulas P; Nemolato S; Faa G
Eur J Histochem; 2011 Jun; 55(2):e20. PubMed ID: 22193299
[TBL] [Abstract][Full Text] [Related]
19. [Dysplastic melanocytic nevus].
Salava A; Ranki A; Saksela O
Duodecim; 2010; 126(21):2492-501. PubMed ID: 21171474
[TBL] [Abstract][Full Text] [Related]
20. [Focal melanocytic atypia in dysplastic nevus cell nevi. Results of a serial section study].
Sigg C; Pelloni F; Schnyder UW
Hautarzt; 1989 Nov; 40(11):701-7. PubMed ID: 2606669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]